HER2-low, despite not being a novel or distinct BC subtype, has been extensively studied in recent literature, consistently revealing its heterogeneity across clinical, morphological, immunohistochemical, and molecular characteristics [2, 16, 29, 33, 36, 66]. Here, ERBB2 is linked to breast cancer.